The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of Pete Foley to its Board of Directors.
CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials
CMTA-STAR announced $1.1 million in grants March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2A
CMTA and Pharnext Enter Biomarker Research Collaboration
Collaboration focused on identifying and characterizing key biomarkers
in Charcot-Marie-Tooth disease Type 1A
Craig Zeltsar Joins CMTA Board of Directors
The Charcot-Marie-Tooth Association today welcomed Craig Zeltsar, principal and co-founder of NNE Marketing, LLC, to its Board of Directors.
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.
David Coldiron Joins CMTA Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.
New Gene Therapy Development Program for CMT2A
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
